- Home
- RVSN vs CELZ Comparison
RVSN vs CELZ Comparison
Compare RVSN & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RVSN | CELZ |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | Israel | United States |
| Employees | 47 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 7.5M |
| IPO Year | 2018 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RVSN | CELZ |
|---|---|---|
| Price | $3.89 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.6K | ★ 599.3K |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.08 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,000.00 |
| Revenue This Year | $860.32 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.17 | $0.62 |
| 52 Week High | $9.39 | $6.25 |
Technical Indicators
Market Signals| Indicator | RVSN | CELZ |
|---|---|---|
| Relative Strength Index (RSI) | 38.26 | 41.17 |
| Support Level | $0.28 | $0.80 |
| Resistance Level | $5.09 | $1.97 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 0.89 | 4.01 |
Price Performance
Historical ComparisonAbout RVSN Rail Vision Ltd.
Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.